Treatment of malignant hypercalcaemia with clodronate.

We have assessed the effects of clodronate (dichloromethylene diphosphonate; Cl2MDP 0.8-3.2g daily by mouth for up to 3 months) in 17 episodes of hypercalcaemia and osteolysis due to carcinoma. Clodronate reduced serum calcium in 14 episodes and bone resorption in all patients. These remained suppre...

Descripción completa

Detalles Bibliográficos
Autores principales: Percival, R. C., Paterson, A. D., Yates, A. J., Beard, D. J., Douglas, D. L., Neal, F. E., Russell, R. G., Kanis, J. A.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1985
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977044/
https://www.ncbi.nlm.nih.gov/pubmed/3158326
Descripción
Sumario:We have assessed the effects of clodronate (dichloromethylene diphosphonate; Cl2MDP 0.8-3.2g daily by mouth for up to 3 months) in 17 episodes of hypercalcaemia and osteolysis due to carcinoma. Clodronate reduced serum calcium in 14 episodes and bone resorption in all patients. These remained suppressed for the duration of treatment, but recurred promptly when treatment was stopped. Clodronate may be a useful measure for controlling hypercalcaemia and osteolysis in patients with carcinoma.

Ejemplares similares